12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vidaza azacitidine: Final Phase I/II data

Final data from 35 evaluable patients in the Phase II portion of a Phase I/II trial showed that Vidaza plus Revlimid lenalidomide led to and overall response rate of 72%, 15 (42%) complete responses, 11 (28%) patients achieving hematologic improvement and 3 cases of progressive disease. Median duration of response was 16 months....

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >